(Q50457858)

14 March 2018

title

Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. (English)

1 reference

14 March 2018

0 references

1 reference

1 reference

Feldman L

1

1 reference

14 March 2018

Efrati S

2

1 reference

14 March 2018

Eviatar E

3

1 reference

14 March 2018

Abramsohn R

4

1 reference

14 March 2018

Yarovoy I

5

1 reference

14 March 2018

Gersch E

6

1 reference

14 March 2018

Averbukh Z

7

1 reference

14 March 2018

Weissgarten J

8

1 reference

14 March 2018

language of work or name

English

0 references

publication date

25 April 2007

1 reference

14 March 2018

published in

Kidney International

1 reference

14 March 2018

volume

72

1 reference

14 March 2018

issue

3

1 reference

14 March 2018

page(s)

359-363

1 reference

14 March 2018

https://scigraph.springernature.com/pub.10.1038/sj.ki.5002295

exact match

0 references

cites work

Insights into ototoxicity. Analogies to nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Permanent gentamicin vestibulotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Recent advances in understanding aminoglycoside ototoxicity and its prevention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Protection from ototoxicity of intraperitoneal gentamicin in guinea pig.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Aspirin to prevent gentamicin-induced hearing loss

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

N-acetyl-L-cysteine for preventing lung reperfusion injury after liver ischemia-reperfusion: a possible dual protective mechanism in a dose-response study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Meningitis-associated hearing loss: protection by adjunctive antioxidant therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Central venous dialysis catheters: catheter-associated infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Current perspectives on inner ear toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Oxidative stress in end-stage renal disease: an emerging threat to patient outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Vitamin E supplementation and cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002295

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5002295

1 reference

14 March 2018

PubMed ID

17457375

1 reference

14 March 2018